Compounded bioidentical hormones vs FDA-approved hormone products
“Bioidentical” describes a hormone's chemical relationship to a hormone the body produces; it does not mean compounded, natural, safer, or FDA approved. FDA-approved bioidentical products exist, while compounded preparations are not FDA approved.
“Bioidentical” and “compounded” are not synonyms. Bioidentical generally describes a hormone with the same chemical and molecular structure as an endogenous hormone. FDA-approved estradiol and micronized progesterone products can fit that description. A compounded preparation is custom-made outside the FDA drug-approval process and is not FDA approved.
The practical choice is not synthetic versus natural. It is an exact hormone, formulation, route, dose, approved or compounded status, clinical indication, evidence, monitoring plan, and reason customization is needed.
Separate four labels that marketing often combines
| Term | What it tells you | What it does not tell you |
|---|---|---|
| Bioidentical | A chemical-structure relationship to a hormone produced by the body | Whether the finished product is FDA approved, compounded, safer, or effective for the proposed use |
| FDA approved | FDA reviewed the finished product for its labeled indication, formulation, manufacturing, labeling, and benefit-risk evidence | That it is right for every person or approved for every wellness claim |
| Compounded | A pharmacy or outsourcing facility prepared a drug under compounding law for a defined need | FDA approval, generic equivalence, or premarket proof of safety, effectiveness, and quality |
| Natural | A broad promotional description with no single regulatory meaning | Source, molecular structure, purity, dose consistency, or lower risk |
ACOG advises against routinely prescribing compounded bioidentical menopausal hormone therapy when FDA-approved formulations exist and explains that marketing claims of greater safety or effectiveness lack supporting evidence.1 Compounding may still have a role when a patient needs a formulation or ingredient avoidance not available in an approved product. That reason should be explicit.
Finished-product status matters more than the ingredient name
FDA approval attaches to a particular finished product and label. A compounded estradiol cream does not become FDA approved because another estradiol product is approved. FDA does not review compounded drugs before marketing for safety, effectiveness, or quality.25
Ask for the product-level identity:
Combination creams deserve extra clarity because a single measured volume can contain several hormones, and absorption can differ by site, base, technique, and skin. A convenient blend can make it harder to adjust one component without changing the others.
Route and product are separate decisions
The pellet, patch, gel, and injection guide compares delivery routes. A route can exist in both approved and compounded forms, so do not infer status from “cream” or “pellet.”
Approved products carry standardized labeling and manufacturing controls; their labels still differ. In 2026 FDA approved classwide and product-specific menopausal hormone labeling changes, reinforcing the need to read the current label rather than relying on an old blanket warning or a sales claim that all risk language disappeared.4
For a compounded route, ask how the pharmacy establishes formulation, potency, sterility when required, stability, packaging, and the beyond-use date. Pharmacy licensure or FDA outsourcing-facility registration is not product approval.
Saliva and urine panels do not create a precision dose by themselves
ACOG does not recommend using adjunct hormone testing to prescribe or dose compounded bioidentical menopausal hormone therapy because supporting data are limited.1 Hormone levels can vary across time, collection conditions, route, assay, and clinical context. A colorful dashboard should not be treated as a direct dosing algorithm without a validated relationship to symptoms, outcomes, and the exact product.
Ask what decision each test changes. Is the test used to confirm a diagnosis, establish a baseline safety field, monitor a known drug effect, or support a proprietary “optimization” range? What happens if symptoms and the number disagree? A useful plan can explain the clinical endpoint without promising that one value defines an ideal state.
Compare claims one at a time
Hormone clinics may bundle relief of menopausal symptoms with weight loss, sexual function, energy, sleep, cognition, skin, muscle, or “anti-aging.” Each claim needs its own indication and evidence. An approved product for vasomotor symptoms does not become approved for general longevity.
Separate the program into:
- diagnosed or defined clinical indication;
- product and route chosen for that indication;
- labeled versus off-label outcomes;
- monitoring for benefit and risk;
- discontinuation or adjustment criteria; and
- promotional outcomes not established by the product record.
Follow the product across prescriber, dispenser, and refill
The first consultation is only one point in a hormone program. Product identity can become less clear when a clinic membership, outside laboratory, dispensing pharmacy, shipment, and later dose change are discussed as one service. Keep a simple chain that can be reconstructed at every refill.
For an FDA-approved product, preserve the manufacturer, product name, strength, dosage form, National Drug Code when available, lot or package information, dispensing pharmacy, and current prescribing information. If the prescriber proposes an off-label use or schedule, separate that use from the product’s approved status. A new generic manufacturer or delivery system may still warrant a fresh product-level comparison rather than being treated as an invisible substitution.
For a compounded preparation, the dispensing label should connect the patient, prescriber, pharmacy, active ingredients, strengths, dosage form, directions, lot or prescription identifier, storage, and beyond-use date. If the formula changes, create a new line in the record. “Same bioidentical program” is not enough when one hormone, concentration, base, route, or pharmacy has changed.
FDA distinguishes patient-specific traditional compounding from work performed by registered outsourcing facilities, but neither pathway turns the finished compounded drug into an FDA-approved product.25 The relevant question is what lawful compounding basis, quality controls, and dispensing chain apply to this preparation—not whether a facility can display an FDA registration number.
Continuity planning matters too. Ask who retains the current medication list and monitoring history if the clinician leaves, the pharmacy changes, shipping is interrupted, or the membership ends. Identify how remaining refills, urgent questions, and transfer of records work. This is not a reason to prefer one product category automatically; it is a way to make either choice traceable over time.
At each renewal, reconcile four things side by side: the clinical indication, the exact product now dispensed, the measured benefit and safety fields, and the reason the current dose or formulation continues.
Build a traceable comparison
- Name the indication. Identify the symptom or condition being evaluated and the evidence used to define it.
- List approved options first. Ask which FDA-approved formulations contain the needed hormone and why they do or do not meet the formulation or ingredient need.
- Document the compounding reason. If customization is proposed, state the patient-specific need and identify the pharmacy, formula, testing, and product status.
- Define monitoring. Record the outcome, timeframe, safety checks, dose-adjustment logic, and who reviews results and symptoms.
- Price the full program. Include visits, drug, labs, supplies, shipping, dose changes, required membership, and continuity if the pharmacy or clinician changes.
The accurate question is not “Are bioidentical hormones better?” It is: which exact hormone product and route meet the identified need, what FDA status and evidence apply, and what specific need—if any—requires compounding? That phrasing preserves the potential value of customization without turning “bioidentical” into an approval or safety claim.
Sources
- American College of Obstetricians and Gynecologists. Compounded bioidentical menopausal hormone therapy. Clinical consensus, reaffirmed 2026, on terminology, evidence, FDA-approved options, compounding indications, testing, counseling, and monitoring. Accessed .
- U.S. Food and Drug Administration. Compounding and the FDA: questions and answers. FDA explanation that compounded drugs are not FDA approved and do not undergo premarket review for safety, effectiveness, or quality. Accessed .
- U.S. Food and Drug Administration. Menopause. FDA consumer resources for approved menopausal hormone products, benefits and risks, labeling, and treatment questions. Accessed .
- U.S. Food and Drug Administration. FDA approves labeling changes for menopausal hormone therapy products. Current 2026 regulatory update illustrating why approved-product labeling must be read by exact product and date rather than as one class slogan. Accessed .
- U.S. Food and Drug Administration. Understanding the risks of compounded drugs. FDA quality and risk framework for patient-specific compounding and registered outsourcing facilities. Accessed .